Navigation Links
PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security

ANNAPOLIS, Md., Oct. 5 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that company President and Chief Executive Officer, David P. Wright and Dr. Valerie Riddle, Vice President and Medical Director, were featured in the Homeland Security Television Channel (HSTV) 30-minute documentary training video entitled, "Deadly Pathogen: Exploring the Anthrax Threat," which was distributed to 65,000 members of the U.S. Department of Homeland Security.

The HSTV Deadly Pathogen documentary video provides an in-depth analysis of the biological agent, Bacillus Anthracis, the bacteria that causes anthrax, and details what this deadly pathogen does to the human body and why it remains such an imminent threat to the security of millions of people worldwide.

The training video was broadcast on the HSTV Threat Matrix Show that investigates current trends and issues in Homeland Security. The show takes an investigative approach to the policy and technology challenges and emerging threats facing the homeland security community.

"We are delighted to share our expertise with the U.S. Department of Homeland Security on anthrax weaponization, anthrax disease pathogenesis, and promising, second generation vaccine product candidates to address this biological threat," commented David P. Wright. "PharmAthene is developing a second generation recombinant protective antigen (rPA) anthrax vaccine called SparVax(TM) to protect civilians and the military and to advance our company goal of becoming the leading provider of best-in-class medical countermeasures for the biodefense industry."

The HSTV Deadly Pathogen: Exploring the Anthrax Threat 30-minute documentary video can be viewed on the link below.

Homeland Security Television Channel

The Homeland Security Television Channel (HSTV) is the world's first online, on-demand television network dedicated to homeland security and global development. HSTV is a 24/7 interactive television channel dedicated to producing broadcast-quality video programs on all aspects of homeland security and the role of global development in fighting terrorism.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements proceeded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at

SOURCE PharmAthene, Inc.

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
2. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
3. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
4. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
5. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
6. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
7. PharmAthene Reports First Quarter 2009 Financial and Operational Results
8. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
9. PharmAthene to Host First Quarter 2009 Conference Call and Webcast on Thursday, May 14, 2009
10. PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
11. PharmAthene Announces $5.5 Million Public Equity Offering
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):